2022
DOI: 10.31083/j.ceog4909206
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background: Many women worldwide are diagnosed with cancer in prepubertal, postpubertal and childbearing age. Oncological treatments can compromise future fertility through different mechanisms mainly depending on the type of treatment and the age of the patient. International societies recommend that cancer patients should receive information regarding the effects of oncological treatments on their reproductive health and cancer survivors should not be discouraged from becoming pregnant. About a quarter of th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 105 publications
0
2
0
Order By: Relevance
“…A recent systematic review of GnRH analogue administration during chemotherapy with commonly used chemotherapeutic drugs for cervical cancer treatment (Paclitaxel and Cisplatin) showed a significant protective effect on ovarian reserve as reflected by patient’s post-therapy hormonal profile [ 27 ]. Although GnRH analogs are used in a fertility-sparing approach, they are applicable in urgent cases and when other non-surgical fertility-preserving options are not feasible [ 28 , 29 , 30 ]. Accumulating evidence suggests that factors influencing the efficacy of GnRH analogues as chemoprotective agents include the type and stage of cancer, the type of chemotherapeutics, pre-treatment of ovarian reserve, as well as a patient’s age [ 26 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…A recent systematic review of GnRH analogue administration during chemotherapy with commonly used chemotherapeutic drugs for cervical cancer treatment (Paclitaxel and Cisplatin) showed a significant protective effect on ovarian reserve as reflected by patient’s post-therapy hormonal profile [ 27 ]. Although GnRH analogs are used in a fertility-sparing approach, they are applicable in urgent cases and when other non-surgical fertility-preserving options are not feasible [ 28 , 29 , 30 ]. Accumulating evidence suggests that factors influencing the efficacy of GnRH analogues as chemoprotective agents include the type and stage of cancer, the type of chemotherapeutics, pre-treatment of ovarian reserve, as well as a patient’s age [ 26 ].…”
Section: Resultsmentioning
confidence: 99%
“…It is crucial to achieve the right balance between oncological safety and cancer treatment outcome on one side and the reproductive ability and pregnancy outcome on the other [ 30 , 38 ]. Surgical treatment of cervical cancer can lead to cervical incompetence with the progression of pregnancy [ 91 ].…”
Section: Resultsmentioning
confidence: 99%